Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

TEL AVIV, Israel and SEATTLE, Wash., June 23 (Korea Bizwire) — Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to [...]